Literature DB >> 3311737

Clinical importance of inducible beta-lactamases in gram-negative bacteria.

C C Sanders1, W E Sanders.   

Abstract

The clinical problems caused by inducible beta-lactamases in certain gram-negative bacteria are being recognized with increasing frequency. These problems include the rapid emergence of multiple beta-lactam resistance during therapy with many of the newer beta-lactam antibiotics. Such multiply resistant organisms are now spreading within the hospital and have become important nosocomial pathogens. This has been a particularly difficult problem for intensive care units, cystic fibrosis centers and burn units where there are clusters of patients who are highly susceptible to infections with organisms like Enterobacter spp., Serratia spp. and Pseudomonas aeruginosa, which possess inducible beta-lactamases. Only through an awareness of these problems, their cause, and restriction of the use of certain newer beta-lactam antibiotics can these problems be controlled.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3311737     DOI: 10.1007/BF02013106

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  33 in total

1.  An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre.

Authors:  S S Pedersen; C Koch; N Høiby; K Rosendal
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

2.  Pseudomonas aeruginosa isolates with modified beta-lactamase inducibility: effects on beta-lactam sensitivity.

Authors:  D M Livermore; R J Williams; M A Lindridge; R C Slack; J D Williams
Journal:  Lancet       Date:  1982-06-26       Impact factor: 79.321

3.  Beta-lactamase alteration of beta-lactam inhibitory zones.

Authors:  F Tausk; C W Stratton
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

4.  Development of resistance to beta-lactam antibiotics with special reference to third-generation cephalosporins.

Authors:  E Collatz; L Gutmann; R Williamson; J F Acar
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

5.  Resistance to cefamandole: derepression of beta-lactamases by cefoxitin and mutation in Enterobacter cloacae.

Authors:  T D Gootz; C C Sanders; R V Goering
Journal:  J Infect Dis       Date:  1982-07       Impact factor: 5.226

6.  The nationwide nosocomial infection rate. A new need for vital statistics.

Authors:  R W Haley; D H Culver; J W White; W M Morgan; T G Emori
Journal:  Am J Epidemiol       Date:  1985-02       Impact factor: 4.897

7.  Affinity of cephalosporins for beta-lactamases as a factor in antibacterial efficacy.

Authors:  D J Phelps; D D Carlton; C A Farrell; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

8.  Survey of the phenotypes of susceptibility to beta-lactams in Enterobacteriaceae at the Pitie-Salpetriere Hospital.

Authors:  V Jarlier; R Bismuth; M H Nicolas; J Nguyen; C Truffot; J Grosset
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

9.  Evaluation of disk approximation and agar dilution induction tests for demonstration of in vitro antagonism of cefotaxime by cefoxitin in Enterobacter species.

Authors:  S W Chandler; F S Nolte
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

10.  Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients.

Authors:  D J Winston; R C Barnes; W G Ho; L S Young; R E Champlin; R P Gale
Journal:  Am J Med       Date:  1984-09       Impact factor: 4.965

View more
  15 in total

1.  Molecular epidemiology of ceftazidime-resistant gram-negative bacilli on inanimate surfaces and their role in cross-transmission during nonoutbreak periods.

Authors:  E M D'Agata; L Venkataraman; P DeGirolami; M Samore
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

2.  Molecular epidemiology of acquisition of ceftazidime-resistant gram-negative bacilli in a nonoutbreak setting.

Authors:  E D'Agata; L Venkataraman; P DeGirolami; M Samore
Journal:  J Clin Microbiol       Date:  1997-10       Impact factor: 5.948

3.  Bacteraemia caused by Escherichia coli and by Enterobacteriaceae producing inducible chromosomal beta-lactamases.

Authors:  P Søgaard; P Tauris
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-03       Impact factor: 3.267

4.  Susceptibility of stably derepressed beta-lactamase producing strains to imipenem and four quinolones.

Authors:  R N Jones; A L Barry
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-02       Impact factor: 3.267

5.  Quantitative analysis of the IgG and IgG subclass immune responses to chromosomal Pseudomonas aeruginosa beta-lactamase in serum from patients with cystic fibrosis by western blotting and laser scanning densitometry.

Authors:  T D Petersen; O Ciofu; T Pressler; B Giwercman; S S Pedersen; N Høiby
Journal:  Thorax       Date:  1996-07       Impact factor: 9.139

6.  Induction of beta-lactamase by cefoxitin in anaerobic intestinal microflora.

Authors:  C Stark; C Edlund; M Hedberg; C E Nord
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-01       Impact factor: 3.267

Review 7.  The antimicrobial activity of cefotaxime: comparative multinational hospital isolate surveys covering 15 years.

Authors:  R N Jones
Journal:  Infection       Date:  1994       Impact factor: 3.553

8.  Septicaemia caused by an Enterobacter cloacae strain varying in resistance against cephalosporins.

Authors:  B M Andersen; I M Dahl; R C George; A Gilfillian
Journal:  Infection       Date:  1989 May-Jun       Impact factor: 3.553

9.  Beta-lactam resistance in Aeromonas spp. caused by inducible beta-lactamases active against penicillins, cephalosporins, and carbapenems.

Authors:  J S Bakken; C C Sanders; R B Clark; M Hori
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

10.  OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa.

Authors:  L M Hall; D M Livermore; D Gur; M Akova; H E Akalin
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.